Treatment Arms showing patients included in the study (n = 28) grouped by Arm A (Ipatasertib + Carboplatin + Paclitaxel, n = 10), Arm B (Ipatasertib + Carboplatin, n = 12), and Arm C (Ipatasertib + Capecitabine + Atezolizumab, n = 6). Best response and PFS are indicated for each arm. Number of patients with samples for correlative analyses including genomic sequencing (n = 27) is indicated (1 patient in arm B did not have sufficient sample for genomic analysis). CR, complete response; PR, partial response; SD, stable disease; PD, progression of disease; PFS, progression–free survival.